Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preoperative Systemic Therapy With FOLFOXIRI Plus Bevacizumab Followed by Cytoreductive Surgery Versus Upfront Cytoreductive Surgery for Resectable Colorectal Peritoneal Metastases: A Randomized Phase 2 Trial

NCT05353582 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05353582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05353582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preoperative Systemic Therapy With FOLFOXIRI Plus Bevacizumab Followed by Cytoreductive Surgery Versus Upfront Cytoreductive Surgery for Resectable Colorectal Peritoneal Metastases: A Randomized Phase 2 Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2022
Completion date
July 1, 2025
Enrollment
168 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, colorectal cancer, colorectal cancer metastatic, colorectal neoplasms, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, peritoneal cancer, peritoneal metastases, peritoneal neoplasms